Hadean Ventures

Neuro Event Labs Oy raises €2.0M investment for commercial expansion in Europe and US market entry of its AI-powered seizure detection device for epilepsy. We are excited to announce that Neuro Event Labs has raised a €2.0M funding from new investor Catalyze Capital as well as existing investor Hadean Ventures, and other shareholders. The proceeds will support commercial expansion in Europe as well as entry into the US market for its lead product Nelli®. Neuro Event Labs Oy, based in Tampere, Finland, is a health technology company dedicated to AI motion diagnostics in Neurology, developing products that improve diagnosis, and thereby treatment, of neurological conditions. The lead product Nelli® is an AI-powered diagnostics and monitoring device for epilepsy, providing doctors with high-quality data of seizures based on video and audio recordings that can be collected in either the patient’s home or in a hospital environment. With over 65 million patients suffering worldwide, epilepsy is one of the most common neurological diseases. The majority of these patients could become seizure-free with appropriate treatment following a proper diagnosis, and with clear characterization of the disease the misdiagnosis rates can be improved. Nelli® unlocks objective, accurate detection and characterization of seizures in a cost-effective and patient-convenient manner. This enables the best possible treatment for epilepsy patients, significantly increasing the chance of becoming seizure-free. Read more: https://lnkd.in/d_AgPhn8 Benjamin Sieters, Kaapo Annala, Ingrid Teigland Akay, MD MBA

Today, we’re proud to announce that Gesynta Pharma has raised 𝗦𝗘𝗞 𝟯𝟬𝟰 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 in Series B funding led by Innovestor Life Science. We'll use this investment primarily for a Phase II clinical trial of 𝘃𝗶𝗽𝗼𝗴𝗹𝗮𝗻𝘀𝘁𝗮𝘁 – a non-hormonal drug candidate aimed at revolutionizing the treatment of 𝗲𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗼𝘀𝗶𝘀, a debilitating inflammatory disease affecting 190 million women globally. “This SEK 304 million funding round marks a pivotal milestone for Gesynta Pharma, demonstrating strong international investor confidence in our approach to treating endometriosis. With these funds, we will advance vipoglanstat towards being Phase III-ready, aiming to provide patients with a disease-modifying treatment option that overcomes the efficacy and tolerability limitations of current therapies,” says Patric Stenberg, CEO of Gesynta Pharma. Read the full press release here: https://lnkd.in/dngfRdWX #Endometriosis #mPGES1 #ChronicPain #AcutePain #WomensHealth #NonHormonal #Vipoglanstat 

We are thrilled to announce that Nelli®, our AI-powered seizure detection and characterization device, has officially received European MDR (Medical Device Regulation) certification as a Class IIa medical device! 🎉 This milestone makes Nelli the only seizure detection and epilepsy monitoring device to achieve MDR compliance, solidifying its role in delivering advanced epilepsy diagnostics and monitoring solutions for both hospital and home environments. 🏥🏠 🔍 What MDR Certification Means: ✅ Stringent clinical evaluation: Demonstrates robust safety and performance backed by rigorous clinical evidence. ✅ Enhanced post-market surveillance: Ensures ongoing safety, functionality, and alignment with the latest medical standards. ✅ Compliance with industry-leading standards: Delivers reliability for healthcare professionals and organizations conducting clinical trials. 💬 Kaapo Annala, founder and CEO of Neuro Event Labs Oy , shared: "This is a major regulatory milestone for Neuro Event Labs on the international epilepsy stage. As we continue to provide objective and accurate biomarkers with advanced AI solutions, Nelli’s MDR certification will reinforce the confidence of healthcare professionals and industry in implementing transformative new technology for epilepsy care." With this achievement, Neuro Event Labs remains committed to driving innovation in epilepsy diagnostics and empowering healthcare professionals with the tools they need to deliver the best care for patients. #Nelli #NeuroEventLabs #Epilepsy #EpilepsyCare

We are happy to share 🎉 a prospective exploratory study conducted at Linköping University Hospital evaluating the diagnostic yield and clinical utility of Nelli® in pharmacoresistant epilepsy patients. This study was published in Epilepsy and Behavior by Fredrik K. Andersson and team. 📄 “Video-based automatic seizure detection in pharmacoresistant epilepsy: A prospective exploratory study” by: Fredrik K. Andersson, Helena Gauffin, Hans Lindehammar & Patrick Vigren MD/PhD 🔹 20 adult patients with pharmacoresistant epilepsy included 🔹Participants were monitored at home using Nelli for a median of 15.5 nights to capture nocturnal seizures 🔹Videos analyzed by a multidisciplinary team of clinical experts to validate Nelli classifications 💡 Enhancing patient safety, refining diagnostics, and improving resource allocation in epilepsy care, Nelli 🔹Diagnosis enabled for 55% of participants, with epileptic seizures identified in 45% 🔹PNES (psychogenic non-epileptic seizures) diagnosed in one participant 81.8% diagnostic yield for motor seizures 🔹Need for vEEG obviated in 20%, new diagnosis in 25%, treatment adjustments for 25%, and therapeutic interventions for 30% of participants ❗The study concluded that Nelli is a valuable tool for evaluating patients with pharmacoresistant epilepsy and motor seizures (e.g., hyperkinetic, tonic, clonic, focal to bilateral tonic-clonic). It facilitates diagnostic workflows and enables more precise anti-seizure treatments. 🎯 With its ability to accurately classify epileptic and non-epileptic events, Nelli® offers a cost-effective and efficient alternative for diagnosing pharmacoresistant epilepsy in outpatient settings. 🔗 Dive deeper into the study: https://lnkd.in/dEKd2NgE

Read about the recently announced cash offer from Pharming Group N.V., on BioStock - Connecting Innovation and Capital: https://lnkd.in/dgdTf66C #m&a #drugdevelopment #mitochondrialdisease #clinicaldevelopment

Welcome, Oncoinvent ASA (ticker: ONCIN)! This morning, we had the pleasure of celebrating Oncoinvent’s listing on Euronext Growth Oslo. A heartfelt congratulations to the entire team on reaching this significant milestone! Oncoinvent specialises in developing innovative cancer treatments. Its flagship therapy involves the injection of radioactive microparticles into the abdominal cavity to target residual cancer cells following surgery. This groundbreaking treatment is specifically designed for patients with colon or ovarian cancer, aiming to offer improved therapeutic options for those affected. We are also proud to highlight that Oncoinvent is the first Norwegian alumnus of IPOready to list. IPOready is Euronext’s pre-IPO programme designed specifically for businesses that are ready to take the next step towards going public. Congratulations once again to Oncoinvent – we look forward to following your journey at Euronext Growth Oslo. #listing #shares #ONCIN #IPOready Euronext Øivind Amundsen | Eirik Høiby Ausland